Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Call number: L301:21
    Keywords: Immunologic Deficiency Syndromes ; Neoplasms, Experimental / immunology ; Disease Models, Animal
    Pages: xiii, 229 p. : ill.
    ISBN: 9783805562706
    Signatur Availability
    L301:21 departmental collection or stack – please contact the library
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-1041
    Keywords: Antitumour agents ; Gallium trinitrate ; Spirogermanium ; Budotitane ; Titanocene dichloride ; metal compounds ; non-platinum-metal complexes
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Abstract The earliest reports on the therapeutic use of metals or metal-containing compounds in cancer and leukemia date from the sixteenth and nineteenth centuries. They were forgotten until the 1960s, when the antitumour activity of the inorganic complex cis-diammine-dichloroplatinum(II) (cisplatin) was discovered. This led to the development of other types of non-organic cytostatic drugs. Cisplatin has developed into one of the most frequently used and most effective cytostatic drugs for the treatment of solid carcinomas. Numerous other metal compounds containing platinum, other platinum metals, and even non-platinum metals were then shown to be effective against tumours in man and experimental tumours in animals. These compounds comprise main-group metallic compounds of gallium, germanium, tin, and bismuth, early-transition metal complexes of titanium, vanadium, niobium, molybdenum, and rhenium, and late-transition metal complexes of ruthenium, rhodium, iridium, platinum, copper, and gold. Several platinum complexes and four non-platinum-metal antitumour agents have so far entered early clinical trials. Gallium trinitrate and spirogermanium have already passed phase II clinical studies and have shown limited cytostatic activity against certain human carcinomas and lymphomas. The two early-transition metal complexes budotitane and titanocene dichloride have just reached the end of phase I clinical trials and have been found to have an unusual pattern of organ toxicity in man. Titanocene dichloride will soon enter phase II clinical studies.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The present study deals with the influence of some bis(η5-cyclopentadienly)titanium(IV) (titanocene) complexes, mainly represented by titanocene dichloride, on the development of several human gastrointestinal (GI) carcinomas (one stomach, seven colon, four sigmoid, and two rectal adenocarcinomas), all xenografted to athymic mice. In 10 of these 14 carcinomas, titanocene dichloride effected growth suppression of 〉50% in comparison with control tumors. In the case of the stomach and two colon adenocarcinomas, absolute decreases in tumor volume occurred during and after the treatment period, resulting in growth delays of 6, 14, and 31 days, respectively. No sensitivity dependence was observed in the degree of tumor differentiation. The findings of the present study confirm the tumor-inhibiting activity of titanocene complexes against human GI adenocarcinomas. These results are noteworthy in view of previous clinical and experimental experience indicating that human adenocarcinomas of the stomach and colon are generally rather insensitive to common cytostatic agents.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Treosulfan (l-threitol-1,4-bismethanesulfonate, Ovastat) is a bifunctional alkylating agent that shows a formal structural similarity to busulfan and is applied clinically to patients suffering from ovarian cancer. The present study demonstrated the pronounced antitumor activity of this drug against three of five human breast carcinomas xenografted to athymic mice. It was shown that treosulfan is capable of inducing irreversible and complete remission of the heterotransplanted human breast carcinomas MDA-MB-436 and MX-1 within 14 days after drug application and of effecting growth inhibition by more than 90% in the MDA-MB-435S xenograft. In all three carcinomas, treosulfan caused more pronounced growth reduction than did equitoxic doses of the alkylator cyclophosphamide. Adriamycin, an intercalating cytostatic agent that is an important component of clinical nonhormonal chemotherapy of breast carcinomas, induced only partial remission of these three xenografts and inhibited the tumor growth by 80%–90% (MDA-MB-436, MX-1) and by 70%–80% (MDA-MB-435S), respectively. In the M 3 xenograft, treosulfan just led to a retardation and stagnation of tumor growth; it was again more effective than Adriamycin but was clearly less active than cyclophosphamide. The FM 2 breast carcinoma, finally, was the only xenograft whose growth was not influenced by treosulfan at doses up to that which was lethal to 50% of the treated mice (LD50 value). These results confirm that treosulfan is effective against human breast carcinomas. Because of this activity as well as the known low toxicity and good clinical compatibility of treosulfan, it should be considered for introduction into nonendocrine chemotherapeutic reginens against human breast carcinomas and investigation in clinical trials.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 5
    Electronic Resource
    Electronic Resource
    Springer
    Cancer chemotherapy and pharmacology 29 (1992), S. 361-366 
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The antitumor activity of the three air-stable bis(cyclopentadienyl)rhenium derivatives [(C5H5)2ReCL2]+Cl−,[(C5H5)2ReCl2]+[AsF6]−, and [(C5H5)2ReCl2]+[SbF6]− was tested against Ehrlich ascites tumor in female CF1 mice. All three compounds contain the group-7 transition metal rhenium in the +5 oxidation state as their central metal atom. They are ionic, salt-like complexes that are composed of the cationic [(C5H5)2ReCl2]+ moiety and one of the negatively charged counterions Cl−, AsF6 −, or SbF6 −. Both the chloro and the hexafluoroarsenate complexes induced a maximal cure rate of 100% when given either in a dose range of 120–160 mg/kg (rhenocene trichloride) or at a single dose of 180 mg/kg (hexafluoroarsenate derivative). The hexafluoroantimonate complex effected a maximal cure rate of only 50% at 60 mg/kg. For the two former compounds, the values for the therapeutic index (Tl) amounted to 1.7 and 2.1, respectively. No impairment of the general condition or pathologic symptoms in the viscera could be detected by observation of the animals during the days following treatment with therapeutic doses or by autopsy of the surviving animals on the key data (day 90). The rhenocene derivatives investigated in the present study represent a new class of antitumor metallocene compounds as well as the first rhenium(V) complexes exerting cytostatic activity.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 6
    Electronic Resource
    Electronic Resource
    Springer
    Cancer chemotherapy and pharmacology 37 (1995), S. 211-221 
    ISSN: 1432-0843
    Keywords: Treosulfan ; Alkylating agent ; Antitumor activity ; Small-cell lung carcinomas ; Non-small-cell lung carcinomas
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Treosulfan (l-threitol 1,4-bismethanesulfonate, Ovastat) is an alkylating agent and a structural analogue of busulfan. It has been established in the clinical chemotherapy of human ovarian carcinomas for several years and has additionally been shown to be effective against xenografted human breast carcinomas. No other human carcinoma is yet known to be sensitive to treosulfan. The present study confirms the pronounced and significant antitumor activity of treosulfan against heterotransplanted human lung carcinomas of both the small-cell and the non-small-cell type. Treosulfan reduced the growth of all four small-cell lung carcinomas that were investigated in a significant manner. It was even more active than equitoxic doses of the clinically approved cytostatics ifosfamide, cisplatin, and etoposide toward three of them and induced long-lasting growth reductions (60–98% of control tumor size) corresponding to partial and nearly complete remissions. In the case of the nine non-small-cell lung carcinomas investigated, treosulfan effected significant growth inhibition of more than 50%, again in all of them, and was more active than the comparative compounds ifosfamide, mitomycin C, and cisplatin at least in one of four epidermoid lung carcinomas, one large-cell carcinoma, and one of three lung adenocarcinomas. These results are remarkable and unexpected, and the present study should be followed rapidly by phase II clinical trials of treosulfan against human lung carcinomas of both the small-cell and the non-small-cell type.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 7
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Five ionic cyclopentadienyltitanium(IV) derivatives were investigated for their activity against fluid Ehrlich ascites tumor. Four compounds were built up by the intact bis(cyclopentadienyl)titanium(IV) (“titanocene”) unit, forming the cationic moiety together with two covalently bound ligands, with certain anions being bonded via electrostatic forces: the acetonitrile complex [(C5H5)2TiCl(NCCH3)]+[FeCl4]- (I), the 2,2′-bipyridyl derivative [(C5H5)2Ti(bipy)]2+[CF3SO3]2 (II), the o-phenanthroline complex [(C5H5)2Ti(phen)]2+[CF3SO3]2 (III), and the N-methyl-o-aminothiophenolate derivative {(C5H5)2Ti[o-S(NHCH3)C6H4]}+I- (IV). Another ionic cyclopentadienyltitanium derivative investigated was the five-coordinate bis(dithiolene) chelate [(C5H5)Ti(1,2,4-S2C6H3CH3)2]-[N(C2H5)4]+ (V), the cyclopentadienyltitanium moiety representing the anionic part of the complex salt. All complexes were ionic, salt-like compounds, distinguished by good water solubility. Whereas complexes I, III, and V, given at optimal dose levels, effected maximal cure rates of only 70%–80%, all animals were cured after receiving complexes II and IV at dose ranges of 200–220 and 240–300 mg/kg, respectively. The antitumor activity of complex I was confirmed against solid experimental tumor systems B16 melanoma, colon 38 carcinoma, and Lewis lung carcinosarcoma. Because of their improved solubility in water and pronounced antitumor activity (especially that of II and IV against fluid Ehrlich ascites tumor), ionic cyclopentadienyl titanium complexes are considered to be an interesting new type of antitumor agent.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 8
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The scope of the present study was to examine whether the cytokinetic phenomena occurring in human tumors under the influence of cisplatin correlate with the response of the tumors to therapy with the drug. Therefore, three strains of heterotransplanted human head and neck carcinomas showing different degrees of sensitivity to cisplatin were investigated by flow cytometry at various intervals after a single administration of cisplatin at four different dose levels (3, 6, 9 or 12 mg/kg). Three types of cell-cycle alterations were observed that depended on the dose of cisplatin and the degree of drug sensitivity shown by the tumors investigated. The obviously weakest kind of tumor reaction was a delay in the G2 cell phase. This phenomenon also occurred in the case of non-responsiveness to therapy, whereby the growth, histological structure and mitotic activity of the tumors remained nearly unaltered after cisplatin treatment. Wich increasing cytotoxicity, additional accumulations of cells in the S phase and, finally, long-lasting blocks at the G1/S boundary were found. The latter phenomenon, which manifested at high dose levels used in sensitive tumors, was obviously irreversible, as it did not completely disappear until the tumor cells had died and been removed by immigrating macrophages. It was always accompanied by severe histological destruction, tumor cell necrotization, and marked depression of the mitotic index. Thus, the hindrance of cell traversal through the S phase obviously represents the main and significant cytokinetic event, which indicates a potent antitumor effect for cisplatin that leads to pronounced tumor regression. This finding supports the hypothesis that inhibition of DNA synthesis is the mechanism underlying the cytotoxicity of cisplatin.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 9
    ISSN: 1432-1335
    Keywords: Titanocene dichloride ; Heterotransplanted human colon adenocarcinoma ; Morphologic alterations
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The influence of the antitumor agent titanocene dichloride on the morphologic appearance of a heterotransplanted human colon adenocarcinoma was investigated. The first alterations in tumor cells manifested 12 h after administration of a single dose (40 mg/kg) and consisted of nuclear changes, such as chromatin condensation, enlargement of the nuclear envelope, structural changes of the nucleoli, and formation of segmented nuclei 12 h later; bundles of microfilaments, lipid droplets and inclusion bodies, often containing cellular debris, occurred in the cytoplasm. Intracytoplasmic virus particles of type A were detectable. They were obviously extruded into the extracellular space by a budding process and became extracellular virus particles of type C. Within 24 h after treatment, the mitotic index decreased from 2.5% to 0.3%. Whereas after administration of a single dose, recovery phenomena took place between 2 and 4 days, the severe destruction induced by 3-fold doses of titanocene dichloride (3×30 mg/kg), was apparently not reversible. These results confirm the tumor-inhibiting potency of titanocene dichloride against human colon adenocarcinoma and underline the discriminatory power of morphologic studies in the preclinical evaluation of cytostatic drugs against heterotransplanted human tumors.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 10
    ISSN: 1432-1335
    Keywords: Titanocen-dihalogenide ; Tumorhemmende Aktivität ; Ehrlich-Aszites-Tumor ; Unterdrückung von Nebenwirkungen ; Titanocene dihalides ; Antitumor activity ; Ehrlich ascites tumor ; Suppression of side effects
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary The antitumor activity of titanocene dihalides (C5H5)2TiX2 with X=F, Cl, Br, I, NCS is investigated against Ehrlich ascites tumor in CF 1 mice. Varying doses of the compounds are applied as single i.p. injections 24 h pt.t. both in non-buffered (pH 1.4–3.9) and buffered (pH 4.2–5.9) solutions or suspensions, all of the substances achieving in optimum doses cure rates of 100% on day 120 p.t.t. This corresponds to I.L.S. values of 600–750% referred to the untreated controls. Some drug-induced side effects, especially the appearance of postperiotonitic symptoms several weeks after i.p. application of higher doses of titanocene dihalides, are strikingly reduced by pH elevation in the injected drug solutions.
    Notes: Zusammenfassung Die tumorhemmende Wirksamkeit von Titanocen-dihalogeniden (C5H5)2TiX2 mit X=F, Cl, Br, J, NCS wird an Ehrlich-Aszites-Tumor-tragenden CF 1-Mäusen untersucht. Verschiedene Dosen der Substanzen werden 24 h p.t.t. als einmalige i.p.-Injektionen sowohl in ungepufferten (pH 1.4–3.9) als auch in gepufferten (pH 4.2–5.9) Lösungen bzw. Suspensionen appliziert. Mit allen Verbindungen werden in optimaler Dosis Heilungsraten von 100% am 120. Tag p.t.t. erreicht. Dies entspricht Verlängerungen der mittleren Überlebensdauer (I.L.S.-Werte) um 600–750% gegenüber den unbehandelten Kontrolltieren. Einige substanzbedingte Nebenwirkungen, insbesondere das Auftreten postperitonitischer Symptome mehrere Wochen nach i.p.-Applikation höherer Dosen der Titanocen-dihalogenide, werden durch pH-Erhöhung in den Injektionslösungen deutlich zurückgedrängt.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...